Saturday 17 October 2026
Export PRGO’s income statement to Excel — free account
Perrigo Company plc
PRGO Healthcare Drug Manufacturers Specialty & Generic
Perrigo Company plc’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, down 2.75% from fiscal 2024. In the quarter to June 2026, revenue fell 3.17%, EPS grew 1,000.0%, free cash flow grew 18.4% and total debt fell 9.78%, each against the same quarter a year earlier. Dividend growth for ten consecutive years; insiders bought in the last twelve months.
16.63
0.15
+0.91%
Follow PRGO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.72 | 0.45 | 0.36 | 0.35 | |
P/FCF ratio |
10.88 | 12.57 | 12.88 | 11.35 | |
P/Operating CF |
59.66 | 10.99 | (13.11) | 17.50 | |
P/B ratio |
0.69 | 0.66 | 0.60 | 0.57 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.47 | 1.18 | 1.14 | 1.05 | |
EV/EBITDA |
10.07 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
16.76 | 21.12 | 25.16 | 22.13 | |
EV/FCF |
22.20 | 32.83 | 41.18 | 34.10 | |
Quick Ratio |
0.94 | 1.13 | 1.06 | 1.05 | |
Current Ratio |
2.51 | 2.76 | 2.72 | 2.32 | |
Net Debt/EBITDA |
20.04 | (2.59) | (11.42) | 23.87 | |
Debt/Assets |
36.14% | 42.65% | 45.50% | 43.30% | |
Debt/Equity |
0.82 | 1.24 | 1.45 | 1.31 | |
Asset Turnover |
0.40 | 0.47 | 0.47 | 0.47 | |
Operating CF/Net income |
6.89 | (0.12) | 0.29 | 1.11 | |
Capex/Depreciation |
(0.21) | (0.28) | (0.14) | (0.15) | |
Interest Coverage |
1.79 | (29.73) | (9.12) | 0.61 | |
Research and Development Expense of Revenue |
2.39% | 1.96% | 2.54% | 2.32% | |
Selling, General and Administrative Expense of Revenue |
23.55% | 23.05% | 27.58% | 24.56% | |
Intangible Assets out of Total Assets |
0.57 | 0.52 | 0.50 | 0.51 | |
Share Based Compensation of Revenue |
1.27% | 1.17% | 1.49% | 0.66% | |
Graham Net Nets |
(0.89) | (1.45) | (1.86) | (1.83) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(1.71%) | (73.85%) | (121.97%) | (120.31%) | |
Free Cash Flow Yield |
9.19% | 7.96% | 7.77% | 8.81% | |
Revenue per Share |
7.53 | 8.01 | 6.99 | 7.35 | |
Operating CF per Share |
0.37 | 1.27 | (0.82) | 0.59 | |
Capex per Share |
(0.13) | (0.18) | (0.09) | (0.10) | |
Free Cash Flow per Share |
0.24 | 1.09 | (0.91) | 0.49 | |
Cash per Share |
3.12 | 3.84 | 2.58 | 2.87 | |
Shareholders Equity per Share |
32.10 | 21.19 | 18.02 | 18.09 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
32.10 | 21.19 | 18.02 | 18.09 | |
Free Cash Flow |
33.00 | 151.00 | (126.00) | 68.30 | |
Working Capital |
1,733.90 | 1,784.50 | 1,714.80 | 1,396.90 | |
Capital Expenditures |
(18.70) | (24.40) | (12.40) | (14.30) | |
Net Current Asset Value |
(2,758.30) | (2,802.30) | (2,772.10) | (2,642.00) | |
EV/EBIT |
22.56 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.02 | 0.01 | 0.01 | |
Price to Operating Income |
11.05 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
715.15 | 627.55 | 706.95 | 694.05 | |
Average Payables |
464.10 | 484.85 | 468.55 | 444.70 | |
Average Inventory |
1,180.40 | 1,115.40 | 1,138.20 | 1,140.00 | |
Average Assets |
10,643.60 | 9,091.45 | 8,871.55 | 8,851.80 | |
Average Common Equity |
4,506.25 | 3,627.45 | 3,431.40 | 3,494.05 |
Columns are period end dates